The tumor cell killing effect of PD-1 inhibitor-mediated cellular immunity further reduces tumor burden [34], and combined treatment with TKIs and PD-1 inhibitors could promote vascular normalization [35]. This evidence concerns the gene PDCD1 and neoplasm.